Firm
Natasha Ahmed said she was drawn to the firm’s commitment to artificial intelligence and tech transactions
As it celebrates its 50th anniversary this year, the firm discusses private equity interest in IP, why the UPC is a key priority, and being a ‘strategic adviser’ to clients
Thomas Rukin discusses IP due diligence, his joy at seeing colleagues succeed, and taking inspiration from Marcus Aurelius
Eva-Maria Strobel reveals some of the firm’s IP achievements and its approach to client relationships
Sponsored
Sponsored
-
Sponsored by Saint Island International Patent & Law OfficesTony Tung-Yang Chang of Saint Island International Patent & Law Offices says plant variety holders will have welcomed the ruling, which resolves previous divergence in local courts over the methodology for assessing infringement
-
Sponsored by RNA, Technology and IP AttorneysRanjan Narula and Eeshani Sharma of RNA, Technology and IP Attorneys explain how India’s legal framework applies to video game characters and question whether it needs to ‘level up’, given the industry’s rapid evolution
-
Sponsored by MaiwaldWilhelm Eger of Maiwald Intellectual Property examines how the Pemetrexed case has influenced European approaches to patent infringement under the doctrine of equivalency and how numbers and measurements are addressed
-
Sponsored by Uni-intel Patent and Trademark Law FirmGump Wang of Uni-intel Patent and Trademark Law Firm explores the strategic value of utility models, which have strong enforcement potential and play a crucial role in China’s patent system
-
Sponsored by AFD China Intellectual Property Law OfficeLinlin Sun and Xia Zheng of AFD China Intellectual Property Law Office cite two key Chinese Supreme People’s Court cases to clarify the conditions under which supplementary experimental data is accepted
-
Sponsored by DEQI Intellectual Property Law CorporationChen Shihua of DEQI Intellectual Property Law Corporation explains China's patent term compensation system, which includes a patent term adjustment for delays and a patent term extension for pharmaceutical patents requiring regulatory approval